ArticleInternational journal of endocrinology2010
Potential role of sugar transporters in cancer and their relationship with anticancer therapy.
Article in International journal of endocrinology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 174 citations in OpenAlex.
- PK-PD modeling of individual lesion FDG-PET response to predict overall survival in patients with sunitinib-treated gastrointestinal stromal tumor.CPT: pharmacometrics & systems pharmacology · 2016Trial
- WNK1 Phosphorylation Sites in TBC1D1 and TBC1D4 Modulate Cell-Surface Abundance of GLUT1.Cells · 2026Article
- The nutrigenomic-epigenetic axis in cancer: from dietary bioactives to precision oncology.Nutrition & metabolism · 2026Review
- Immunohistochemical study of glucose transporter protein expression in oral lichen planus.Dental research journal · 2026Article
- A novel glycogene-related signature for prognostic prediction and immune microenvironment assessment in kidney renal clear cell carcinoma.Annals of medicine · 2025Article
- Article
- The molecular basis of Human FN3K mediated phosphorylation of glycated substrates.Nature communications · 2025Article
- Exploring Metabolic Approaches for Epithelial Ovarian Cancer Therapy.Journal of cellular physiology · 2025Review
- Envisioning Glucose Transporters (GLUTs and SGLTs) as Novel Intervention against Cancer: Drug Discovery Perspective and Targeting Approach.Current drug targets · 2025Review
- A closed-loop modular multiorgan-on-chips platform for self-sustaining and tightly controlled oxygenation.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- The molecular basis of Human FN3K mediated phosphorylation of glycated substrate.bioRxiv : the preprint server for biology · 2024Article
- Photosensitizer-thioglycosides enhance photodynamic therapy by augmenting cellular uptake.Carbohydrate research · 2024Article
- Dietary phenolic compounds as promising therapeutic agents for diabetes and its complications: A comprehensive review.Food science & nutrition · 2024Review
- Synthesis and Biological Evaluation of a Novel Sugar-Conjugated Platinum(II) Complex Having a Tumor-Targeting Effect.ACS omega · 2024Article
- Receptor-mediated transcytosis for brain delivery of therapeutics: receptor classes and criteria.Frontiers in drug delivery · 2024Review
- Differentiation of Salivary Gland and Salivary Gland Tumor Tissue via Raman Imaging Combined with Multivariate Data Analysis.Diagnostics (Basel, Switzerland) · 2023Article
- Study on Saccharide-Glucose Receptor Interactions with the Use of Surface Plasmon Resonance.International journal of molecular sciences · 2023Article
- Sweet Battle of the Epimers─Continued Exploration of Monosaccharide-Derived Delivery Agents for Boron Neutron Capture Therapy.Molecular pharmaceutics · 2023Article
- Lactate from glycolysis regulates inflammatory macrophage polarization in breast cancer.Cancer immunology, immunotherapy : CII · 2023Article
- Quantitative proteomics identified a novel invasion biomarker associated with EMT in pituitary adenomas.Frontiers in endocrinology · 2023Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sugars, primarily glucose and fructose, are the main energy source of cells. Because of their hydrophilic nature, cells use a number of transporter proteins to introduce sugars through their plasma membrane. Cancer cells are well known to display an enhanced sugar uptake and consumption. In fact, sugar transporters are deregulated in cancer cells so they incorporate higher amounts of sugar than normal cells. In this paper, we compile the most significant data available about biochemical and biological properties of sugar transporters in normal tissues and we review the available information about sugar carrier expression in different types of cancer. Moreover, we describe the possible pharmacological interactions between drugs currently used in anticancer therapy and the expression or function of facilitative sugar transporters. Finally, we also go into the insights about the future design of drugs targeted against sugar utilization in cancer cells.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.